CN111713625A - Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof - Google Patents

Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof Download PDF

Info

Publication number
CN111713625A
CN111713625A CN202010538017.8A CN202010538017A CN111713625A CN 111713625 A CN111713625 A CN 111713625A CN 202010538017 A CN202010538017 A CN 202010538017A CN 111713625 A CN111713625 A CN 111713625A
Authority
CN
China
Prior art keywords
parts
bacillus coagulans
eczema
lactobacillus plantarum
solid beverage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010538017.8A
Other languages
Chinese (zh)
Inventor
方曙光
蒋大成
严涛
陈珂可
冯胜鹏
朱建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Wecare Biotechnology Co ltd
Original Assignee
Jiangsu Wecare Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Wecare Biotechnology Co ltd filed Critical Jiangsu Wecare Biotechnology Co ltd
Priority to CN202010538017.8A priority Critical patent/CN111713625A/en
Publication of CN111713625A publication Critical patent/CN111713625A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a bacillus coagulans solid beverage with an effect of relieving eczema and a preparation method thereof, and relates to the field of functional foods, wherein the solid beverage comprises the following raw materials in parts by weight: 20-30 parts of oat beta-glucan, 10-15 parts of inulin, 3-5 parts of purslane extract, 30-35 parts of maltodextrin, 3-5 parts of bacillus coagulans and 1-5 parts of lactobacillus plantarum. The bacillus coagulans BC99 and the lactobacillus plantarum LP90 adopted by the invention have the effects of relieving eczema, inhibiting the growth of pathogenic microorganisms and promoting metabolism, and meanwhile, functional raw materials of oat beta-glucan and purslane extract are added to endow the functional food with better skin barrier maintenance, participation in skin hydration, acute inflammation resistance and excessive acute expression of epidermal mucosa, so that local symptoms of epidemic eczema are relieved.

Description

Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof
Technical Field
The invention relates to the field of functional foods, in particular to a bacillus coagulans solid beverage with an effect of relieving eczema and a preparation method thereof.
Background
Eczema is one of clinically common allergic and inflammatory skin diseases, and is a common disease and a frequently encountered disease of dermatology. It is seen that at any age, both men and women may develop the disease without sex difference. It is a skin inflammatory reaction with obvious exudation tendency, and the skin lesion is a polymorphic lesion mainly comprising a pimple, has exudation tendency, is recurrent, has overlapped alternation of acute and chronic periods, is accompanied by severe itching, and is better developed in the elbow fossa, fossa, two sides of the neck, the wrist, the back and the like. The incidence rate of eczema is high, and accounts for 15-25% of the outpatient amount of dermatology, wherein the acute eczema accounts for 52.4%. One survey in the united states showed that the prevalence of various forms of eczema in the general population is 18%; various investigations in the uk have shown that eczema patients constitute 17-30% of all skin patients. It has been reported that the prevalence of eczema increases 2-10 fold in the last 30 years.
The causes of the disease are generally related to the allergic constitution with genetic tendency, the allergens often include food (such as milk, eggs, food eaten by mothers, such as seafood, and the like), inhalants such as pollen, fur fibers, chemical volatile substances, and the like, other contact substances (such as strong wind, pollen, catkin, ice cold water, and the like), vaccinations and the like, and the diseases can be caused and aggravated by the allergens, and the skin cuticle is thin in the infant period, the skin capillaries are rich, and the allergens are also the main mechanisms of the allergic reaction which is easy to occur.
Recent studies have shown that eczema can be caused by infection of various microorganisms, and staphylococcus aureus, branchial sympathetic bacteria and the like can be detected at eczema lesions. The main key points of treating eczema are sterilization, itching relieving, inflammation diminishing and moisture retention. At present, the eczema is mainly treated clinically by glucocorticoid preparations, tar preparations, immunomodulators or antibiotic external preparations. However, long-term clinical application of hormones and antibiotics is prone to cause local adverse reactions such as drug resistance, skin atrophy, telangiectasia, pigmentation and the like.
The condensed budding Paulobacter, also called a budding Lactobacillus, belongs to gram-positive bacteria, is facultative anaerobic, can produce lactic acid, can produce bacteriostatic active substances, and can inhibit the growth of certain putrefactive and pathogenic microorganisms. Because it is non-toxic and harmless to human body, and does not change the characteristics of food itself, it can be used in food industry field. Can inhibit intestinal pathogenic bacteria in animal intestinal tract, and can be used in medical health promotion field.
Disclosure of Invention
The invention provides a bacillus coagulans solid beverage with an effect of relieving eczema and a preparation method thereof, and solves the problem that the existing method for treating eczema usually adopts external corticoid drugs, and has obvious side effects.
In order to solve the technical problems, the technical scheme of the invention is as follows:
the bacillus coagulans solid beverage with the effect of relieving eczema comprises the following raw materials in parts by weight:
20-30 parts of oat beta-glucan, 10-15 parts of inulin, 3-5 parts of purslane extract, 30-35 parts of maltodextrin, 3-5 parts of bacillus coagulans and 1-5 parts of lactobacillus plantarum.
Preferably, the Bacillus coagulans is Bacillus coagulans BC99, the Bacillus coagulans BC99 is named as Bacillus coagulans with the preservation number as follows: CGMCC No. 19487.
Preferably, the Lactobacillus plantarum is Lactobacillus plantarum Lp90, the Lactobacillus plantarum Lp90 is named Lactobacillus plantarum, and the deposit number is: CGMCC No. 10453.
The preparation method of the bacillus coagulans solid beverage with the effect of relieving eczema comprises the steps of weighing oat beta-glucan, inulin, purslane extract, maltodextrin, bacillus coagulans and lactobacillus plantarum in required parts by weight, and uniformly stirring.
By adopting the technical scheme, the bacillus coagulans BC99 and the lactobacillus plantarum LP90 adopted by the invention have the effects of relieving eczema, inhibiting the growth of pathogenic microorganisms and promoting metabolism, and meanwhile, functional raw materials of oat beta-glucan and purslane extract are added to endow the functional food with better skin barrier maintenance, participation in skin hydration, acute inflammation resistance and inhibition of excessive acute expression of epidermal mucosa, so that local symptoms of wet plague are relieved; the invention takes natural substances as sources, can act on human bodies mildly and without irritation after being mixed according to a certain proportion, and has the effects of bacteriostasis, relieving, diminishing inflammation and resisting allergy. The probiotics is used as a health agent, the existing medicines are not applicable to partial people without generating side effects, and the wide applicable population of the probiotics is not limited by age, sex and medical history.
Detailed Description
The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
Weighing 24 parts of oat beta-glucan, 11 parts of inulin, 4 parts of purslane extract, 32 parts of maltodextrin, 994 parts of bacillus coagulans BC and 902 parts of lactobacillus plantarum Lp, and uniformly stirring.
Bacillus coagulans BC99 deposit unit code: CGMCC-China general microbiological culture Collection center; address: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North; the detection result of the bacillus coagulans BC99 is as follows: survival; the preservation date is as follows: year 2020, 03, 18 months; the preservation number is: CGMCC No. 19487; and (3) classification and naming: bacillus coagulans Bacillus coagulons.
Lactobacillus plantarum Lp90 deposit unit code: CGMCC-China general microbiological culture Collection center; address: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North; the detection result of the lactobacillus plantarum Lp90 is as follows: survival; the preservation date is as follows: 27 months 01 in 2015; the preservation number is: CGMCC No. 10453; and (3) classification and naming: lactobacillus plantarum.
Oat beta-glucan is a naturally occurring polysaccharide with 1, 3-glycosyl as the main chain and 1, 6-glycosyl as the side chain, obtained by the method described in patent application No. 201510725996.7, namely, by fermentation and extraction of schizophyllum commune. The proliferation rate of skin cells can be improved, the generation of collagen and elastin is promoted, the damaged skin is helped to be updated and repaired, and the healing of scars is promoted; the skin moisture is kept, the moisture retention and the tightening smoothness of the skin are improved, histamine release and degranulation of mast cells are effectively inhibited, sensitive skin is relieved, and skin inflammation is reduced.
The condensed budding Paulobacter, also called a budding Lactobacillus, belongs to gram-positive bacteria, is facultative anaerobic, can produce lactic acid, can produce bacteriostatic active substances, and can inhibit the growth of certain putrefactive and pathogenic microorganisms. Has no toxicity and harm to human body, does not change the characteristics of food, and can better inhibit pathogenic bacteria in animal intestinal tract.
After being ingested, the inulin promotes the growth of intestinal epithelium to enable columnar cells and goblet cells to grow, the mucus of the goblet cells increases, the integrity of colon and the whole intestinal mucosa is sewed, and DNA of the damaged epithelium is repaired. Can significantly increase the growth of bifidobacteria, inhibit the growth of putrefying bacteria, reduce the generation of toxic products, adsorb and chelate toxic fermentation products, remove putrefying products and bacterial toxins, thereby reducing the burden of the liver and promoting the synthesis of nutrients.
The herba Portulacae extractive solution is prepared by dissolving bioactive substances obtained by low-temperature extraction method in 39.5% butanediol solution, has broad-spectrum antibacterial, antiinflammatory and antiallergic effects, and can promote physiological function recovery of epithelial cells.
Example 2
Weighing 20 parts of oat beta-glucan, 10 parts of inulin, 3 parts of purslane extract, 30 parts of maltodextrin, 993 parts of bacillus coagulans BC and 901 parts of lactobacillus plantarum, and uniformly stirring.
Example 3
Weighing 30 parts of oat beta-glucan, 15 parts of inulin, 5 parts of purslane extract, 35 parts of maltodextrin, 995 parts of bacillus coagulans BC and 905 parts of lactobacillus plantarum, and uniformly stirring.
Example 4
The effect of relieving eczema is carried out animal experiment research
Experimental materials: ICR mice 72, 18-22 g.
The experimental process comprises the following steps: the 72 mice were randomly divided into 6 groups of 12 mice each, which served as a blank group, a model group, bacillus coagulans functional food high, medium, and low dose groups, and a positive control group, respectively. Removing mouse abdominal hair with electric hair clipper and electric hair cutter, and applying 5% 2, 4-Dinitrochlorobenzene (DNCB)30 μ L to skin for first sensitization of model group, Bacillus coagulans functional food high, medium and low dosage groups and positive control group; on day 5, a second antigen challenge was performed by applying 50. mu.L of 0.2% DNCB to a 2cm by 2cm shaved area of the back, the symmetrical shaved area of the left back being free of drug as a control. After that, the excitation was performed 1 time every 3d for 3 times. On the 9 th day, the right back of the mouse is observed to obviously have erythema, edema, pimple, erosion or exudation compared with the left back, which indicates that the molding is successful.
After 10 days of the experiment, the mice of each group were treated with drugs, and the high, medium and low dose groups of the bacillus coagulans functional food of example 1 were intragastrically filled with 1g, 0.5g and 0.25g of the bacillus coagulans functional food of example 1 dissolved in 2mL of distilled water, respectively, every day, the positive control group was intragastrically filled with 2mL of phellodendron bark solution, and the model group and the blank control group were intragastrically filled with 2mL of distilled water, respectively. The medicine is administered according to group and dosage 3 times a day for 10 days on the day of successful model building.
1. Comparison of degree of swelling of skin on the back and inhibition rate of the mice
After the experiment, the animals were sacrificed, and the skin of the right dermatitis area of the back of the mouse and the symmetrical healthy skin of the left side were cut off respectively without removing adipose tissues using sterile surgical scissors, and the skin of the same area was punched out respectively using a circular punch having a diameter of 6mm, and weighed using an analytical balance. The degree of swelling and inhibition rate of the back skin of the mice in each experimental group are detected.
Group of Animal number (only) Swelling degree (mg, x + -SD) Inhibition ratio (%)
Blank group 12 6.21 /
Model set 12 16.84±2.43 /
High dose 12 9.38±1.47* 70.18±9.63
Middle dose 12 12.41±6.47* 41.67±7.88
Low dose 12 14.68±5.15 20.32±22.41
Positive control 12 7.79±14.26 85.14±11.57
Note: p <0.05 compared to control group
The results are shown in the table above, which shows that the bacillus coagulans functional food can obviously reduce the swelling degree of the mouse ear caused by 5 percent of 2, 4-dinitrochlorobenzene, and has obvious inhibition effect on swelling inflammation of the mouse ear.
2. Comparison of inflammatory cytokines in eczema lesions in mice
After the test is finished, the skin of the model-making part is taken down from the abdomen of the mouse by adopting a sterile surgical scissors, the tissue is quickly fixed in 4 percent paraformaldehyde liquid immersion, and the expression levels of IFN-gamma Ra, IL-2 and TNF-alpha in the skin tissue of the skin lesion of each experimental group are detected.
Figure BDA0002537746900000041
Figure BDA0002537746900000051
Note:#compared with the model group, the model group is compared,*compared with the hormone group, is less than 0.05,##compared with the model group, the model group is compared,**compared with a positive control group, the ratio is less than 0.01。
2.1 comparison of FN-gamma Ra amounts in eczema lesions in mice
From the experimental results shown in the table above, it can be seen that: the high-dose, medium-dose, low-dose and positive control groups can suppress the reduction of FN-gamma Ra in the eczema wound skin damage of the mice caused by the 2, 4-dinitrochlorobenzene, and the 5 groups have statistically significant difference (P <0.05) compared with the model group. The medium dose group had statistical significance in promoting FN- γ Ra in the skin compared to the positive control group (P < 0.05); the difference between the high dose group and the model group was not statistically significant (P > 0.05)). Due to the dose-effect relationship between the low, medium and high doses, the difference in comparison (P <0.01) between the low, medium and high dose groups was statistically significant. From the X + S values: for improving the improvement of FN-gamma Ra in the skin tissues of the mouse eczema model, the result shows that the overall curative effect of the positive control group is still higher than that of the low, medium and high dose groups; the high dose group has slightly stronger curative effect than the medium dose group, the curative effect is close to that of the control group, and the low dose group has low curative effect.
2.2 comparison of IL-2 levels in eczema lesions in mice
From the experimental results shown in the table above, it can be seen that: the high-dose, medium-dose, low-dose and positive control groups have obvious effect on reducing IL-2 in the eczema wound skin damage of the mice by using the 2, 4-dinitrochlorobenzene, and the 5 groups have statistically significant difference (P is less than 0.01) compared with the model group. The IL-2 in the medium-dose group is statistically different from that in the western-medicine group in the reduction of the wound skin damage (P < 0.05); the low, medium and high doses have dose-effect relationship, and the difference of the low dose group, the medium dose group and the high dose group (P <0.01) has obvious statistical significance. From the X + S values: for the improvement of IL-2 in the skin tissue of the mouse eczema model, the result shows that the overall efficacy of the positive control group is higher than that of the high-dose group; the middle dose group was slightly less effective than the high dose group, with the low dose group having the lowest efficacy.
2.3 comparison of TNF-alpha amounts in eczema lesions in mice
From the experimental results shown in the table above, it can be seen that: the high-dose, medium-dose, low-dose and positive control groups have obvious effect on reducing TNF-alpha in the eczema wound skin lesion of the mouse by using 2, 4-dinitrochlorobenzene, and the 5 groups have obvious difference (P is less than 0.01) in the phylogenetic aspect after being compared with the model group. The high dose group was statistically significant in reducing TNF- α in the skin compared to the difference between the hormone groups (P < 0.05); because of the dose-effect relationship between the low, medium and high doses, the difference of the low, medium and high dose groups (P <0.01) is statistically significant. From the X + S values: for the improvement of reducing TNF-alpha in the skin tissue of the mouse eczema model, the result shows that the whole curative effect of the positive control group is still higher than that of the dose group; the middle dose group was slightly less effective than the high dose group, with the low dose group having the lowest efficacy.
In conclusion, the bacillus coagulans functional food shows anti-inflammatory inhibition effect on 2, 4-dinitrochlorobenzene-induced auricular edema, inflammation and other chronic inflammation models, wherein the anti-inflammatory, skin-moistening and anti-allergy effects are better in high-concentration effect and slightly better than medium-concentration effect.
After the mouse takes the composition, the effective components in the composition can be absorbed by human body to indirectly improve the generation of IL-2 and FN-gamma Ra of skin lesions of the mouse with eczema, thereby effectively reducing the bovine cost of TNF-alpha and being beneficial to the repair and recovery of the skin lesions of the eczema. The experimental results show that: the high-concentration solid beverage has good curative effect; wherein the effects of the low and medium concentration solid beverages are similar, and the positive control group has stronger effects on improving FN-gamma Ra and IL-2 in skin lesions of the eczema mice and indirectly reducing the generation of TNF-alpha than the different gradient dose groups.
Although the results of statistical analysis and experiments show that each index of the hormone group is obviously superior to that of each dosage group, the frequency, times, recurrence rate, hormone side effect and the like of taking are considered in the long term, and the probiotic solid preparation has the advantages of safety and less toxic and side effects compared with other hormone medicines based on the consideration, and has better clinical curative effect, simplicity and convenience.
3. Comparison of degree of liver injury in mice of each experimental group
Blood is taken from retrobulbar venous plexus to measure serum ALT, meanwhile, cervical vertebra is pulled off to kill mice and take liver, liver homogenate is prepared, supernatant is taken to measure liver TG, the ALT and TG value changes of the mice of each group are compared, and the influence of bacillus coagulans functional food on the liver of the mice is verified.
Group of Animal number (only) ALT/U·L-1 TG/mg·Kg-1liver
Blank group 12 122.66±13.79 14.9±1.0
Model set 12 121.21±12.54 14.7±1.9
High dose 12 127.87±9.62 15.5±2.0
Middle dose 12 124.58±6.97 15.2±2.7
Low dose 12 124.24±16.78 15.0±1.8
The results in the table show that compared with the normal control group mice, the ALTT and TG values of the bacillus coagulans functional food high and medium dosage group in the example 1 have no significant difference, and the functional food has no obvious damage to the liver and can be used for adjuvant therapy of eczema.
The embodiments of the present invention have been described in detail, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.

Claims (4)

1. A bacillus coagulans solid beverage with an effect of relieving eczema is characterized in that: the feed comprises the following raw materials in parts by weight:
20-30 parts of oat beta-glucan, 10-15 parts of inulin, 3-5 parts of purslane extract, 30-35 parts of maltodextrin, 3-5 parts of bacillus coagulans and 1-5 parts of lactobacillus plantarum.
2. The bacillus coagulans solid beverage with the efficacy of relieving eczema as claimed in claim 1, wherein: the Bacillus coagulans is Bacillus coagulans BC99, the Bacillus coagulans BC99 is named as Bacillus coagulans, and the preservation number is as follows: CGMCC No. 19487.
3. The bacillus coagulans solid beverage with the efficacy of relieving eczema as claimed in claim 1, wherein: the lactobacillus plantarum is lactobacillus plantarum Lp90, the lactobacillus plantarum Lp90 is named lactobacillus plantarum, and the preservation number is as follows: CGMCC No. 10453.
4. A method for preparing a bacillus coagulans solid beverage with an eczema relieving effect according to any one of claims 1 to 3, wherein the bacillus coagulans solid beverage is prepared by the following steps: weighing oat beta-glucan, inulin, purslane extract, maltodextrin, bacillus coagulans and lactobacillus plantarum in required weight parts, and uniformly stirring.
CN202010538017.8A 2020-06-12 2020-06-12 Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof Pending CN111713625A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010538017.8A CN111713625A (en) 2020-06-12 2020-06-12 Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010538017.8A CN111713625A (en) 2020-06-12 2020-06-12 Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof

Publications (1)

Publication Number Publication Date
CN111713625A true CN111713625A (en) 2020-09-29

Family

ID=72566625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010538017.8A Pending CN111713625A (en) 2020-06-12 2020-06-12 Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111713625A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112425776A (en) * 2020-12-11 2021-03-02 安徽国膳生物科技有限公司 Medicated diet for people with eczema
CN115607577A (en) * 2022-10-09 2023-01-17 微康益生菌(苏州)股份有限公司 Probiotic with effect of relieving stomatitis as well as preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104839681A (en) * 2015-04-14 2015-08-19 劲膳美生物科技股份有限公司 Medical formula food for people with damp heat constitution
CN106075120A (en) * 2016-07-01 2016-11-09 宁波希诺亚海洋生物科技有限公司 A kind of Eczema Creams agent
CN107212378A (en) * 2016-03-22 2017-09-29 内蒙古伊利实业集团股份有限公司 A kind of function composition with regulation enteron aisle and its application
CN108850774A (en) * 2018-07-04 2018-11-23 于银行 One compound health-preserving beverage of seed ginseng Rui and preparation method thereof
CN108991327A (en) * 2018-07-24 2018-12-14 北京奥维森基因健康科技有限公司 A kind of probiotics solid beverage and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104839681A (en) * 2015-04-14 2015-08-19 劲膳美生物科技股份有限公司 Medical formula food for people with damp heat constitution
CN107212378A (en) * 2016-03-22 2017-09-29 内蒙古伊利实业集团股份有限公司 A kind of function composition with regulation enteron aisle and its application
CN106075120A (en) * 2016-07-01 2016-11-09 宁波希诺亚海洋生物科技有限公司 A kind of Eczema Creams agent
CN108850774A (en) * 2018-07-04 2018-11-23 于银行 One compound health-preserving beverage of seed ginseng Rui and preparation method thereof
CN108991327A (en) * 2018-07-24 2018-12-14 北京奥维森基因健康科技有限公司 A kind of probiotics solid beverage and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
涂艳华等: "新型益生菌凝结芽孢杆菌BC99在食品中的应用", 《食品工业科技》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112425776A (en) * 2020-12-11 2021-03-02 安徽国膳生物科技有限公司 Medicated diet for people with eczema
CN115607577A (en) * 2022-10-09 2023-01-17 微康益生菌(苏州)股份有限公司 Probiotic with effect of relieving stomatitis as well as preparation method and application thereof
CN115607577B (en) * 2022-10-09 2024-01-30 微康益生菌(苏州)股份有限公司 Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof

Similar Documents

Publication Publication Date Title
TWI607758B (en) Lactobacillus paracasei strain gmnl-653 and composition having the same for improving psoriasis symptoms
CN112999261B (en) Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof
KR101734960B1 (en) Leuconostoc holzapfelii stain for preventing depilation, improving hair growth or improving sexual disfunction, and composition comprising the same
CN111713625A (en) Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof
CN103157095B (en) Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof
KR100871837B1 (en) Bacterial Culture Having Effects of Suppressing Dermatitis Development and Accelerating Skin Wound Healing, and Product Using The Same
CN109985069B (en) Probiotic compositions and uses thereof
CN111297961A (en) Dong medicine for promoting wound healing
CN114712440A (en) Dai medicine composition for relieving senile cutaneous pruritus and preparation and application thereof
CN114452308A (en) Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent
CN115607577B (en) Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof
US11826380B2 (en) Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments
CN107468999A (en) A kind of fermentation composition with beauty treatment and eliminating spot function and preparation method thereof
CN105853463A (en) Traditional Chinese medicinal preparation for treating carbuncle ulcer and promoting muscle growth as well as preparing method and application thereof
CN112057601A (en) Preparation method of active probiotic freeze-dried powder and application of active probiotic freeze-dried powder in skin and gynecological diseases
Widjanarko et al. Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats
US20060127518A1 (en) Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
CN111588773B (en) Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof
CN114767708B (en) Stable gynecological antibacterial composition and gynecological care solution
CN109320625B (en) Extraction method and application of angelica sinensis polysaccharide
CN105168638A (en) Traditional Chinese medicinal liquid band aid for preventing and treating bedsore complicated with bacterial infection
CN105106475A (en) Traditional Chinese medicine gel used for treating toxin-accumulating rotting and ulcerating type bedsores during clinical nursing
CN113995775A (en) Probiotic foot mask with foot protection effect and preparation method thereof
CN104491554B (en) A kind of medicine for treating mastitis and preparation method thereof
CN115844993A (en) A Chinese medicinal disinfectant for oral cavity and skin, and its preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200929